Repatha (evolocumab) - Articles and news items

ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim

New data adds to understanding of Repatha® (evolocumab) in multiple patient populations

Industry news / 23 August 2016 / Amgen

Amgen will present data evaluating Repatha® (evolocumab) at the upcoming European Society of Cardiology (ESC) Congress 2016 in Rome…

NICE recommends five drugs to treat four different conditions

Industry news / 22 June 2016 / Victoria White, Digital Content Producer

NICE has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS…

NICE recommends alirocumab and evolocumab in draft guidance

Industry news / 6 May 2016 / Victoria White, Digital Content Producer

Alirocumab and evolocumab are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia…

Positive topline results from GAUSS-3 trial of Repatha

Industry news / 5 February 2016 / Victoria White

The Phase 3 GAUSS-3 trial evaluating Amgen’s Repatha (evolocumab) in patients with high cholesterol who cannot tolerate statins met its co-primary endpoints…

NICE says ‘no’ to Amgen’s Repatha in draft guidance

Industry news / 18 November 2015 / Victoria White

The NICE Committee felt the question whether Repatha (evolocumab) would reduce angina, heart attacks and strokes remains unanswered…

FDA approves LDL cholesterol drug Repatha

Industry news / 28 August 2015 / Victoria White

Repatha, the second drug approved in a new class of drugs known as PCSK9 inhibitors, has been approved by the FDA for some patients who are unable to get their LDL cholesterol under control with current treatment options…

EC approves Amgen’s cholesterol-lowering medication Repatha

Industry news / 21 July 2015 / Victoria White

The EC has granted marketing authorisation for Repatha for the treatment of patients with uncontrolled cholesterol who require additional LDL-C reduction…

Amgen receives positive CHMP opinion for use of Repatha for the treatment of high cholesterol

Industry news / 22 May 2015 / Victoria White

The CHMP has adopted a positive opinion for the marketing authorisation of Amgen’s Repatha for use in certain patients with high cholesterol…

FDA to review Amgen’s Repatha as a treatment for high cholesterol

Industry news / 30 April 2015 / Victoria White

The FDA will review data supporting Amgen’s Biologics License Application (BLA) for Repatha (evolocumab) for the treatment of high cholesterol…


Thomson Reuters names most promising drugs of 2015

Industry news / 24 March 2015 / Victoria White

The Intellectual Property and Science business of Thomson Reuters has released the 2015 edition of its annual Drugs to Watch report…


Amgen presents long-term data showing efficacy and safety of investigational cholesterol-lowering medication evolocumab across lipid And LDL-C levels

Industry news / 19 November 2014 / Amgen

Additional data analysis showed every two week and monthly dosing regimens of evolocumab were clinically equivalent…


Biologics to Complement Statins in Cholesterol Treatment Space, says GlobalData Analyst

Industry news / 12 November 2014 / GlobalData

Biologics will play an influential role in shaping the future of cardiovascular (CV) drug treatment, as these and other emerging therapies will compete for patients who cannot tolerate statins, or for whom statin therapy alone is insufficient, according to an analyst with research and consulting firm GlobalData…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...